Thereafter, we performed diagnostic comparisons between the new versus classical t-tau biomarkers (with N-p-tau assays included for proof of concept) across the Alzheimer’s disease continuum and other neurological disorders using the same Simoa platform. The gene discussed is MAPT; the disease is Alzheimer disease.